Université de Sherbrooke
Welcome,         Profile    Billing    Logout  
 59 Trials 
117 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Langlois, Marie-France
ROGMF-2, NCT00991640: Impact of an Integrated Obesity Management System on Patient's Care

Active, not recruiting
N/A
460
Canada
2-day preceptorship on obesity management
Université de Sherbrooke, Canadian Institutes of Health Research (CIHR)
Obesity
12/13
12/25
NCT02478853: Impact of a Regional Program Agir Sur Sa SantE

Active, not recruiting
N/A
1000
Canada
Implementation of a new regional care framework
Université de Sherbrooke
Diabetes Mellitus, Type 2, Obesity, Hypertension, Dyslipidemias, Cardiovascular Diseases, Smoking
12/17
12/25
NCT03908099: Fit-for-Fertility Multicenter Randomized Controlled Trial

Recruiting
N/A
616
Canada
Fit-For-Fertility program, Standard of care, Fertilty care
Université de Sherbrooke, Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Ferring Pharmaceuticals
Obesity, Infertility, Female
04/28
10/28
Turcotte, Eric
NCT04842071: 18F-sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment

Recruiting
3
2500
Canada
18F-sodium fluoride, 18F-NaF
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke
Bone Cancer, Articular Disease, Infectious Disease
12/25
12/25
NCT04824014: 4FMFES-PET Imaging of ER+ Advanced Breast Cancers

Recruiting
2
150
Canada
4FMFES-PET, 4,16α-[16α-18F]difluoro-11β-methoxyestradiol PET
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Canadian Cancer Society (CCS), Université de Sherbrooke
ER+ Breast Cancer
12/25
12/25
NCT05974579: Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated with Amyotrophic Lateral Sclerosis

Active, not recruiting
1
12
Canada
89Zr-DFO-AP-101
Université de Sherbrooke, Eli Lilly and Company, Chorus Wellness Inc.
Amyotrophic Lateral Sclerosis
12/24
03/25
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours

Recruiting
1
110
Canada, US
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Fusion Pharmaceuticals Inc., AstraZeneca
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/26
12/27
GB8, NCT05092945: Brown Adipose Tissue Metabolism in Type 2 Diabetes

Recruiting
N/A
40
Canada
Cold exposure, Oral Nicotinic acid, Niacin 500 (Jamp Pharma) NPN 00557412
Université de Sherbrooke
Type 2 Diabetes
09/25
12/25
Lougheed, Diane
ISAR, NCT04045587: International Severe Asthma Registry: Canadian Cohort

Recruiting
N/A
714
Canada
University of British Columbia, University of Alberta, University of Toronto, Laval University, McGill University, Université de Sherbrooke, The Ottawa Hospital, Queen's University, University of Saskatchewan, Western University, Canada
Severe Asthma
12/27
12/28
Schiff, David
NCT00978458: Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Active, not recruiting
3
540
US
temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Neurotoxicity
12/24
12/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT02498951: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Terminated
2
32
US
Cognitive Assessment, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment
OHSU Knight Cancer Institute, Genentech, Inc., National Cancer Institute (NCI), Oregon Health and Science University, Providence Health & Services
Central Nervous System B-Cell Non-Hodgkin Lymphoma
03/24
03/24
S22-11168, NCT06359379: Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Recruiting
2
54
US
Ropidoxuridine, 5-iodo-2-pyrimidinone-2'-deoxyribose
Shuttle Pharmaceuticals, Inc.
Glioblastoma, IDH-wildtype
08/26
02/27
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
INSIGhT, NCT02977780: INdividualized Screening Trial of Innovative Glioblastoma Therapy

Recruiting
2
460
US
Temozolomide, Temodar, Neratinib, QBS10072S
Patrick Wen, MD, Eli Lilly and Company, Celgene, Puma Biotechnology, Inc., Accelerate Brain Cancer Cure, Quadriga Biosciences, Inc.
Glioblastoma
02/27
04/27
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Active, not recruiting
2
95
US
safusidenib, DS-1001b, AB-218
Nuvation Bio Inc., AnHeart Therapeutics Inc.
Glioma
03/27
07/27
NCT03914742: BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Completed
1/2
67
US
PARP Inhibitor BGB-290, BGB-290, PARP, Inhibitor BGB-290, Temozolomide, Temodar, Methazolastone, Therapeutic Conventional Surgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), BeiGene
IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
10/23
10/23
NCI-2018-01560, NCT03604978: Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

Recruiting
1/2
38
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
National Cancer Institute (NCI)
Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
11/25
11/25
NCT05432804: Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recruiting
1/2
97
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT 330, KPT-330, KPT330, Nexpovio, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI)
MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
06/26
06/26
Colman, Howard
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT03224767: Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma

Active, not recruiting
2
24
US
Vemurafenib, Cobimetinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
BRAF V600E Mutation Present, Papillary Craniopharyngioma
10/26
08/28
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
NCT03994796: Genetic Testing in Guiding Treatment for Patients with Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/26
06/28
NCT05859334: Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Suspended
2
35
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Optical Coherence Tomography, OCT, Optical Coherence Tomography (OCT)
National Cancer Institute (NCI)
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma
10/26
10/26
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Active, not recruiting
2
95
US
safusidenib, DS-1001b, AB-218
Nuvation Bio Inc., AnHeart Therapeutics Inc.
Glioma
03/27
07/27
DETERMINE, NCT06194929: Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting
1/2
33
US
Defactinib, Avutometinib, Encorafenib
University of Utah, Verastem, Inc.
Melanoma
01/28
01/30
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
PNOC025, NCT05169944: Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

Completed
1
13
US
Magrolimab, Anti-CD47 Monoclonal Antibody
University of California, San Francisco, Gilead Sciences
Brain Cancer, Malignant Brain Tumor, Recurrent Brain Tumor, Progressive Malignant Brain Tumor, Brain Tumor, Pediatric, Brain Tumor Adult
09/24
09/24
NCT05739942: Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Recruiting
1
48
Europe, US, RoW
[177Lu]Lu-NeoB, Lu-NeoB, [68Ga]Ga-NeoB, Ga-NeoB, Temozolomide
Novartis Pharmaceuticals
Newly Diagnosed and Recurrent Glioblastoma
02/26
08/31
Pasquier, Jean-Charles
PROBIO, NCT04050189: Validation of the In-utero Transmission of Probiotics

Completed
2
52
Canada
Natural products: Probiotics, Placebo
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Lallemand Health Solutions
In Utero Drug Exposure
08/23
11/23
PROVID-LD, NCT05080244: WHO COVID-19 - Evaluation of the Efficacy of Probiotics to Reduce the Occurrence of Long COVID

Completed
N/A
618
Canada
Probiotics, Placebo
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Lallemand Health Solutions
COVID-19
12/22
12/22
PROBIO3D, NCT05195151: Modification of the COVID-19 Vaccine Response by an Intervention on the Intestinal Flora

Completed
N/A
592
Canada
Taking capsule containing probiotics or placebo
Université de Sherbrooke, CHU de Quebec-Universite Laval
COVID-19, Vaccine Reaction, Elderly
07/24
07/24
Baillargeon, Jean-Patrice
NCT06402825: Follow-up of Children Born from a Preconception Lifestyle Intervention in Women with Obesity and Infertility

Enrolling by invitation
N/A
50
Canada
Fit-for-Fertility program
Université de Sherbrooke
Obesity, Childhood, Lifestyle Intervention, Preconception Care
12/24
12/24
NCT03908099: Fit-for-Fertility Multicenter Randomized Controlled Trial

Recruiting
N/A
616
Canada
Fit-For-Fertility program, Standard of care, Fertilty care
Université de Sherbrooke, Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Ferring Pharmaceuticals
Obesity, Infertility, Female
04/28
10/28
LePage, Serge
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruiting
2
456
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
MAPLE-CHF, NCT05859048: Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure

Recruiting
N/A
1360
Canada
NT-proBNP, AI echocardiogram, electrocardiogram, Cardiovascular physical examination
Cardiology Research UBC, AstraZeneca, Centre for Cardiovascular Innovation, NHS Greater Glasgow & Clyde, HeartLife Foundation, Canadian Heart Function Alliance, Montreal Heart Institute
Heart Failure
01/27
01/29
Moussa, Ahmed
NCT04572048: Longitudinal One Year Vs Single Day NRP Training.

Recruiting
N/A
250
Canada
Single-day NRP Training, longitudinal NRP training
Ahmed Moussa
Nurse Training in Neonatal Resuscitation
01/26
01/26
OPTION SAFE, NCT05838690: Optimizing Tracheal Intubation Outcomes and Neonatal Safety

Recruiting
N/A
3000
Canada, US
Personalized Intubation Safety (PINS) Bundle, PINS Bundle
Children's Hospital of Philadelphia, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infant, Intubation Complication
04/27
06/27
NEAR4KIDs, NCT02493478: Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

Recruiting
N/A
150000
Europe, Canada, Japan, US, RoW
Children's Hospital of Philadelphia, Agency for Healthcare Research and Quality (AHRQ)
Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
01/30
01/30
Lamontagne, Francois
SNAP, NCT05137119: Staphylococcus Aureus Network Adaptive Platform Trial

Recruiting
4
8000
Europe, Canada, RoW
Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute
Staphylococcus Aureus Bacteremia
12/28
12/28
ARBs CORONA II, NCT04606563: Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Terminated
3
341
Europe, Canada
Losartan, Cozaar, Valsartan, Diovan, Azilsartan, Edarbi, Candesartan, Atacand, Eprosartan, Teventen, Irbesartan, Avapro, Olmesartan, Olmetec, Telmisartan, Micardis
University of British Columbia, Canadian Institutes of Health Research (CIHR)
Covid19, SARS-CoV Infection
04/22
04/22
REVISE, NCT03374800 / 2020-000483-27: Re-EValuating the Inhibition of Stress Erosions () Trial

Completed
3
4800
Europe, Canada, US, RoW
Placebo (0.9% saline), normal saline; NaCl 0.9%, Pantoprazole, Protonix
McMaster University, Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, National Health and Medical Research Council, Australia
Gastrointestinal Hemorrhage (Clinically Important, Upper)
10/23
01/24
CATCO, NCT04330690: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Active, not recruiting
3
2900
Canada
Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide
Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
COVID-19
03/24
05/24
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
ATTACC-CAP, NCT05848713: AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Recruiting
3
4000
Canada, US, RoW
Heparin
University of Manitoba, Canadian Institutes of Health Research (CIHR), Research Manitoba, Ozmosis Research Inc., Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Critical Care Trials Group, AVANTI
Community-acquired Pneumonia
03/28
03/29
CEPEC, NCT06605144: Canadian Critical Care Comparative Effectiveness Platform

Not yet recruiting
N/A
6500
NA
1- Vasopressors - Mean arterial pressure 55-59, 2- Vasopressors - Mean arterial pressure 60-65, 3- Vasopressors - Mean arterial pressure 66-69, 4- Vasopressors - Mean arterial pressure 70-75
Université de Sherbrooke
Intensive Care Unit ICU
12/29
06/30
ARBS CORONA I, NCT04510623: Host Response Mediators in Coronavirus (COVID-19) Infection

Recruiting
N/A
500
Canada
ARBs and/or ACE inhibitors, Usual Care
University of British Columbia, Canadian Institutes of Health Research (CIHR), British Columbia Centre for Disease Control, McGill University Health Centre/Research Institute of the McGill University Health Centre, University of Toronto, University of Ottawa, University of Calgary, University of Alberta, University of Victoria, Wuhan University, Peking Union Medical College, University of Pennsylvania
COVID-19, SARS-CoV2
06/21
06/22
Tousignant-Laflamme, Yannick
NCT04893369: Determining the Effectiveness of the Pain and Disability Drivers Management Model on the Management of Low Back Pain

Recruiting
N/A
84
Canada
The Low Back Pain and Disability Drivers Management model, Low back pain clinical practice guidelines
Université de Sherbrooke
Low Back Pain
05/22
05/22
NCT04979403: Efficacy of Two Physiotherapy's Approaches in Chronic Low Back Pain: Is Addressing Psychosocial Factors Beneficial?

Completed
N/A
40
Canada
Physiotherapy
Laval University, Centre Interdisciplinaire de Recherche en Réadaptation et Intégration Sociale, Fonds de la Recherche en Santé du Québec, Ordre professionnel de la physiothérapie du Québec
Low Back Pain, Recurrent
10/22
10/22
Drappatz, Jan
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT03212274: Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
2
145
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
07/25
07/25
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
INSIGhT, NCT02977780: INdividualized Screening Trial of Innovative Glioblastoma Therapy

Recruiting
2
460
US
Temozolomide, Temodar, Neratinib, QBS10072S
Patrick Wen, MD, Eli Lilly and Company, Celgene, Puma Biotechnology, Inc., Accelerate Brain Cancer Cure, Quadriga Biosciences, Inc.
Glioblastoma
02/27
04/27
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
HTX-GBM-01, NCT05736406: A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma

Recruiting
1/2
12
US
5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2, Pentalafen®, 5-aminolevulinic acid hydrochloride, Heliance® Solution, 5-ALA PDT, 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
Hemerion Therapeutics
Primary Glioblastoma
12/25
07/26
NCT05109728: A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Recruiting
1
60
Europe, US
[177Lu]Lu-DOTA-TATE, Lutathera, Lutetium (177Lu)oxodotreotide, Lutetium Lu 177dotatate, [68Ga]Ga-DOTA-TATE, Temozolomide, Radiotherapy
Novartis Pharmaceuticals
Glioblastoma
08/25
08/26
NCT03423628: A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Jan 2024 - Dec 2024: Data from trial in combination with radiation therapy for brain metastases
Recruiting
1
180
Europe, Japan, US
Radiation Therapy, Radiotherapy, Radiation treatment, RT, AZD1390, ATM inhibitor
AstraZeneca
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
09/26
09/26
Mathieu, David
TRACS, NCT02568124: Tranexamic Acid in Chronic Subdural Hematomas

Recruiting
2/3
130
Canada
Tranexamic Acid, Cyklokapron, Placebo
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke
Chronic Subdural Hematoma
12/24
06/25
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
BLAST, NCT06047951: Brain Low-risk Aneurysm Stereotactic Radiosurgical Trial

Recruiting
N/A
40
Canada
Stereotactic RadioSurgery (SRS), Gamma Knife SRS
Dr David Mathieu, Université de Sherbrooke, Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Intracranial Aneurysm
08/28
08/28
Lamontagne, François
ALTER-AKI, NCT04705896: Albumin To Enhance Recovery After Acute Kidney Injury

Recruiting
4
856
Canada
20-25% Albumin fluid (100 mL), 0.9% Normal Saline (100 mL)
Ottawa Hospital Research Institute, The Physicians' Services Incorporated Foundation, The Kidney Foundation of Canada, The Ottawa Hospital Academic Medical Organization (TOHAMO) Innovation Fund Grant., Canadian Institutes of Health Research (CIHR), Canadian Blood Services, Héma-Québec
Acute Kidney Injury, Renal Replacement Therapy, Hypotension, Critical Illness
08/25
10/25
FISSH, NCT03677102: Fluids in Septic Shock

Recruiting
2/3
1096
Canada, RoW
higher chloride crystalloid, lower chloride crystalloid
McMaster University, The Physicians' Services Incorporated Foundation, Canadian Institutes of Health Research (CIHR)
Sepsis, Septic Shock
11/25
03/26
CINERGY, NCT05148715: Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function

Recruiting
2
414
Canada
Tacrolimus, Prograf, Placebo
Université de Sherbrooke, McMaster University
Organ Transplant Failure or Rejection, Brain Death, Ischemic Reperfusion Injury
01/25
01/26
OVATION-65, NCT03431181: Optimal VAsopressor TitraTION in Patients 65 Years and Older

Active, not recruiting
N/A
159
Canada
MAP target 60-65 mmHg, Usual care
Université de Sherbrooke
Vasopressors, Hypotension, Mean Arterial Pressure Targets, Usual Care
02/20
12/24
BALANCE, NCT03005145: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Completed
N/A
3622
Europe, Canada, US, RoW
7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.
Sunnybrook Health Sciences Centre
Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
05/23
08/23
NCT06537609: A Platform Trial for Gram Negative Bloodstream Infections

Recruiting
N/A
2500
Canada
De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement, Cephalosporin VS Carbapenem for low risk AmpC organisms, Routine follow-up blood culture VS No routine follow-up blood culture
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR)
Gram-negative Bacteremia
04/27
04/28
Roberge, Pasquale
NCT05124639: Clinical Trial of a Group Self-management Support Program for Anxiety Disorders

Active, not recruiting
N/A
414
Canada
Group self-management support program for anxiety disorders, SMS+TAU
Université de Sherbrooke, Canadian Institutes of Health Research (CIHR), Relief
Panic Disorder, Agoraphobia, Social Anxiety Disorder, Generalized Anxiety Disorder
03/24
12/26
postnataIiCBT, NCT06778096: Transdiagnostic Internet Cognitive-behavior Therapy for Mixed Anxiety and Depressive Symptoms in Postnatal Women

Not yet recruiting
N/A
226
Canada
Postnatal anxiety and depression iCBTprogram, Postnatal iCBT
Université de Sherbrooke, Canadian Institutes of Health Research (CIHR), Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke, Centre intégré de santé et services sociaux de la Montérégie-Centre, Centre intégré de santé et services sociaux de la Montérégie-Ouest, Centre intégré de santé et services sociaux de la Montérégie-Est, Champlain Local Health Integration Network
Anxiety, Postnatal Depression
04/26
04/26
Kida, Yuri
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
NCT04617002: Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Available
N/A
US
ONC201 (dordaviprone)
Chimerix
Glioma, H3 K27M
 
 
Tousignant, Michel
NCT03593174: Étude de l'efficacité du Pansement Rigide Amovible Sous Vide à Titre de modalité de Pansement Post-amputation Tibiale

Recruiting
N/A
10
Canada
Ossur Rigid Dressing, Elastic Bandage
Université de Sherbrooke
Trans-tibial Amputations
01/22
06/22
NCT04893369: Determining the Effectiveness of the Pain and Disability Drivers Management Model on the Management of Low Back Pain

Recruiting
N/A
84
Canada
The Low Back Pain and Disability Drivers Management model, Low back pain clinical practice guidelines
Université de Sherbrooke
Low Back Pain
05/22
05/22
Caouette, Georges
NCT04430790 / 2019-003666-41: Doxapram Therapy in Preterm Infants (DOXA Trial)

Recruiting
3
396
Europe, Canada
Doxapram, Dopram, Placebo, Placebo (for Doxapram)
Erasmus Medical Center, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Nederlands Neonataal Netwerk (N3), the Netherlands, Universitaire Ziekenhuizen KU Leuven, Maternal, Infant, Child and Youth Research Network (MICYRN)
Apnea of Prematurity, Respiratory Insufficiency
05/26
05/34
NCT04572048: Longitudinal One Year Vs Single Day NRP Training.

Recruiting
N/A
250
Canada
Single-day NRP Training, longitudinal NRP training
Ahmed Moussa
Nurse Training in Neonatal Resuscitation
01/26
01/26
Kingsford, Rachel
SAVE, NCT03422198: Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

Recruiting
3
188
US
Vaginal Cuff Brachytherapy, best practice, standard of care, standard therapy, Short course vaginal cuff brachytherapy, BRACHYTHERAPY, internal radiation, Internal Radiation Brachytherapy, Internal Radiation Therapy, Radiation Brachytherapy
University of Utah
Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma, Uterine Corpus Sarcoma
11/26
10/29
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
PROSTA-Q, NCT04252625: Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis

Terminated
2
10
US
Q-Urol, Placebo
University of Utah, Farr Labs, LLC
Prostate Adenocarcinoma
12/23
01/24
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Active, not recruiting
2
95
US
safusidenib, DS-1001b, AB-218
Nuvation Bio Inc., AnHeart Therapeutics Inc.
Glioma
03/27
07/27
DETERMINE, NCT06194929: Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting
1/2
33
US
Defactinib, Avutometinib, Encorafenib
University of Utah, Verastem, Inc.
Melanoma
01/28
01/30
RT-PACE, NCT04683653: Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

Recruiting
1/2
100
US
Hypofractionated Radiation, Clinical Follow-Up and Assessments
University of Chicago
Endometrial Cancer
05/25
05/25
PIONEER, NCT04846309: Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy

Recruiting
1
16
US
Radiation, FMISO PET CT
University of Utah
Esophageal Cancer
04/25
04/26
NCT05023551: Study of DSP-0390 in Patients with Recurrent High-Grade Glioma

Active, not recruiting
1
39
Japan, US
DSP-0390
Sumitomo Pharma America, Inc.
High Grade Glioma, Glioblastoma Multiforme
09/26
10/26
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
Med-RT, NCT06165653: Guided Meditation During Radiation Therapy for Brain Tumors

Recruiting
N/A
30
US
5-Minute, Audio-Recorded Guided Mediation Practice
University of Utah
Brain Neoplasms
01/26
01/28
Léonard, Guillaume
NCT05006066: The Effect of the Nature And Frequency of a Stimulation on the Amplitude of the Temporal Summation of Pain

Recruiting
N/A
34
Canada
Temporal Summation
Université de Sherbrooke, Canadian Institutes of Health Research (CIHR)
Healthy
08/22
08/22
NCT05370274: Using Cranial Nerve Non-invasive Neuromodulation to Improve Pain and Upper Extremity Function After a Stroke

Completed
N/A
12
Canada
Strength training intervention, Cranial nerve non-invasive neuromodulation (CN-NINM)
Université de Sherbrooke
Stroke
06/23
06/23
NCT04896827: DNIC Using Deep Learning and Artificial Intelligence

Suspended
N/A
244
Canada
Conditioned pain modulation test
Université de Sherbrooke, Lucine, Centre for Research of CHUS (CRCHUS)
Chronic Pain
12/25
12/25
NCT05316623: Using Peripheral Neurostimulation to Improve Work Rehabilitation

Recruiting
N/A
24
Canada
TENS, Transcutaneous electrical nerve stimulation, Peripheral neurostimulation
Université de Sherbrooke, Réseau Provincial De Recherche En Adaptation-Réadaptation (REPAR), Réseau québécois de recherche sur le vieillissement (RQRV)
Chronic Pain
08/24
12/24
NCT04332939: Motor System Activation With Transcranial Direct Current Stimulation and Physical Exercise to Reduce Pain in Elderly

Recruiting
N/A
32
Canada
transcranial direct current stimulation, Physical exercise
Université de Sherbrooke
Chronic Pain
10/23
12/24
NCT04555278: Combining Non-invasive Brain Stimulation and Exercise to Treat Low Back Pain

Completed
N/A
140
Canada
Active rTMS, Repetitive Transcranial Magnetic Stimulation, Sham rTMS, Sham Repetitive Transcranial Magnetic Stimulation, Motor Control Exercises
Hugo Massé-Alarie, Pfizer, The Canadian Pain Society, Canadian Institutes of Health Research (CIHR)
Chronic Low-back Pain
03/24
03/24
NCT06228573: Transcranial Direct Current Stimulation and Yoga for Knee Osteoarthritis

Recruiting
N/A
68
Canada
Yoga
McMaster University, The Arthritis Society, Canada
Knee Osteoarthritis
09/25
12/25
Woodburn, CJ
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Active, not recruiting
2
95
US
safusidenib, DS-1001b, AB-218
Nuvation Bio Inc., AnHeart Therapeutics Inc.
Glioma
03/27
07/27
Masse, Édith
NCT04572048: Longitudinal One Year Vs Single Day NRP Training.

Recruiting
N/A
250
Canada
Single-day NRP Training, longitudinal NRP training
Ahmed Moussa
Nurse Training in Neonatal Resuscitation
01/26
01/26
Boissy, Patrick
CycliP, NCT06392438: Cyclosporine and Intense Pulsed Light for Dry Eye in Contact Lens Users

Recruiting
3
44
Canada
CycloSPORINE Ophthalmic, Cequa, Intense Pulsed Light, IPL M22 Lumenis, Sham Intense Pulse Light, Sham-IPL M22 Lumenis
Université de Sherbrooke
Dry Eye, Contact Lens Complication
09/25
09/25
Coburn, Bryan
SNAP, NCT05137119: Staphylococcus Aureus Network Adaptive Platform Trial

Recruiting
4
8000
Europe, Canada, RoW
Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute
Staphylococcus Aureus Bacteremia
12/28
12/28
 

Download Options